Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry

References

• Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 52; http://dx.doi.org/10.1038/nri2747; PMID: 20414207
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413 - 5; http://dx.doi.org/10.4161/mabs.19931; PMID: 22531442
   PubMed Web of Science ®Google Scholar
• Ambrogelly A, Liu YH, Li H, Mengisen S, Yao B, Cannon-Carlson S, et al. Characterization of antibody variants during process development The tale of incomplete processing of N-terminal secretion peptide. MAbs 2012; 4:1 - 9; http://dx.doi.org/10.4161/mabs.21614; PMID: 22327425
   PubMed Web of Science ®Google Scholar
• Damen CWN, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 2009; 20:2021 - 33; http://dx.doi.org/10.1016/j.jasms.2009.07.017; PMID: 19744865
   PubMed Web of Science ®Google Scholar
• Committee for medicinal products for human use (CHMP), European Medicines Agency (EMA). Guideline on development, production, characterization and specifications for monoclonal antibodies and related products 2009; EMEA/CHMP/BWP/157653/2007.
   Google Scholar
• McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011; 3:209 - 17; http://dx.doi.org/10.4161/mabs.3.2.15005; PMID: 21441787
   PubMed Web of Science ®Google Scholar
• Reichert JM, Beck A, Iyer H. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK. MAbs 2009; 1:394 - 416; http://dx.doi.org/10.4161/mabs.1.5.9630; PMID: 20065643
   PubMedGoogle Scholar
• Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 2009; 28:147 - 76; http://dx.doi.org/10.1002/mas.20190; PMID: 18720354
   PubMed Web of Science ®Google Scholar
• Harris RJ, Chin ET, Macchi F, Keck RG, Shyong BJ, Ling VT, et al. Analytical characterization of monoclonal antibodies: linking structure to function. Current Trends in Monoclonal Antibody Development and Manufacturing, Springer 2010; 193-205.
   Google Scholar
• Wagner-Rousset E, Bednarczyk A, Bussat MC, Colas O, Corvaïa N, Schaeffer C, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872:23 - 37; http://dx.doi.org/10.1016/j.jchromb.2008.03.032; PMID: 18672411
   PubMed Web of Science ®Google Scholar
• Beck A, Bussat MC, Zorn N, Robillard V, Klinguer-Hamour C, Chenu S, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:203 - 18; http://dx.doi.org/10.1016/j.jchromb.2004.06.052; PMID: 15833284
   PubMed Web of Science ®Google Scholar
• Xie H, Chakraborty A, Ahn J, Yu YQ, Dakshinamoorthy DP, Gilar M, et al. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010; 2:379 - 94; PMID: 20458189
   PubMed Web of Science ®Google Scholar
• Alvarez M, Tremintin G, Wang J, Eng M, Kao YH, Jeong J, et al. On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format. Anal Biochem 2011; 419:17 - 25; http://dx.doi.org/10.1016/j.ab.2011.07.033; PMID: 21867674
   PubMed Web of Science ®Google Scholar
• Michels DA, Tu AW, McElroy W, Voehringer D, Salas-Solano O. Charge heterogeneity of monoclonal antibodies by multiplexed imaged capillary isoelectric focusing immunoassay with chemiluminescence detection. Anal Chem 2012; 84:5380 - 6; http://dx.doi.org/10.1021/ac3008847; PMID: 22663182
   PubMed Web of Science ®Google Scholar
• Kaschak T, Boyd D, Yan B. Characterization of glycation in an IgG1 by capillary electrophoresis sodium dodecyl sulfate and mass spectrometry. Anal Biochem 2011; 417:256 - 63; http://dx.doi.org/10.1016/j.ab.2011.06.024; PMID: 21756870
   PubMed Web of Science ®Google Scholar
• Rustandi RR, Wang Y. Use of CE-SDS gel for characterization of monoclonal antibody hinge region clipping due to copper and high pH stress. Electrophoresis 2011; 32:3078 - 84; http://dx.doi.org/10.1002/elps.201100186; PMID: 22145164
   PubMed Web of Science ®Google Scholar
• Moini M. Simplifying CE-MS operation. 2. Interfacing low-flow separation techniques to mass spectrometry using a porous tip. Anal Chem 2007; 79:4241 - 6; http://dx.doi.org/10.1021/ac0704560; PMID: 17447730
   PubMed Web of Science ®Google Scholar
• Haselberg R, Ratnayake CK, de Jong GJ, Somsen GW. Performance of a sheathless porous tip sprayer for capillary electrophoresis-electrospray ionization-mass spectrometry of intact proteins. J Chromatogr A 2010; 1217:7605 - 11; http://dx.doi.org/10.1016/j.chroma.2010.10.006; PMID: 20970804
   PubMed Web of Science ®Google Scholar
• Faserl K, Sarg B, Kremser L, Lindner H. Optimization and evaluation of a sheathless capillary electrophoresis-electrospray ionization mass spectrometry platform for peptide analysis: comparison to liquid chromatography-electrospray ionization mass spectrometry. Anal Chem 2011; 83:7297 - 305; http://dx.doi.org/10.1021/ac2010372; PMID: 21848273
   PubMed Web of Science ®Google Scholar
• Busnel JM, Schoenmaker B, Ramautar R, Carrasco-Pancorbo A, Ratnayake C, Feitelson JS, et al. High capacity capillary electrophoresis-electrospray ionization mass spectrometry: coupling a porous sheathless interface with transient-isotachophoresis. Anal Chem 2010; 82:9476 - 83; http://dx.doi.org/10.1021/ac102159d; PMID: 21028888
   PubMed Web of Science ®Google Scholar
• Ramautar R, Busnel JM, Deelder AM, Mayboroda OA. Enhancing the coverage of the urinary metabolome by sheathless capillary electrophoresis-mass spectrometry. Anal Chem 2012; 84:885 - 92; http://dx.doi.org/10.1021/ac202407v; PMID: 22148170
   PubMed Web of Science ®Google Scholar
• Haselberg R, Harmsen S, Dolman MEM, de Jong GJ, Kok RJ, Somsen GW. Characterization of drug-lysozyme conjugates by sheathless capillary electrophoresis-time-of-flight mass spectrometry. Anal Chim Acta 2011; 698:77 - 83; http://dx.doi.org/10.1016/j.aca.2011.04.050; PMID: 21645662
   PubMed Web of Science ®Google Scholar
• Whitmore CD, Gennaro LA. Capillary electrophoresis-mass spectrometry methods for tryptic peptide mapping of therapeutic antibodies. Electrophoresis 2012; 33:1550 - 6; http://dx.doi.org/10.1002/elps.201200066; PMID: 22736356
   PubMed Web of Science ®Google Scholar
• Demeule B, Palais C, Machaidze G, Gurny R, Arvinte T. New methods allowing the detection of protein aggregates: a case study on trastuzumab. MAbs 2009; 1:142 - 50; http://dx.doi.org/10.4161/mabs.1.2.7632; PMID: 20061815
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39 - 51; http://dx.doi.org/10.1056/NEJMra043186; PMID: 17611206
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285 - 9; http://dx.doi.org/10.1073/pnas.89.10.4285; PMID: 1350088
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, et al. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 2001; 752:233 - 45; http://dx.doi.org/10.1016/S0378-4347(00)00548-X; PMID: 11270864
   PubMed Web of Science ®Google Scholar
• Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 2009; 392:145 - 54; http://dx.doi.org/10.1016/j.ab.2009.05.043; PMID: 19497295
   PubMed Web of Science ®Google Scholar
• Gennaro LA, Salas-Solano O, Ma S. Capillary electrophoresis-mass spectrometry as a characterization tool for therapeutic proteins. Anal Biochem 2006; 355:249 - 58; http://dx.doi.org/10.1016/j.ab.2006.04.002; PMID: 16712766
   PubMed Web of Science ®Google Scholar
• Beck A, Sanglier-Cianférani S, Van Dorsselaer A. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal Chem 2012; 84:4637 - 46; http://dx.doi.org/10.1021/ac3002885; PMID: 22510259
   PubMed Web of Science ®Google Scholar
• Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 2010; 9:1716 - 28; http://dx.doi.org/10.1074/mcp.M900540-MCP200; PMID: 20103567
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008; 97:2426 - 47; http://dx.doi.org/10.1002/jps.21180; PMID: 17828757
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005; 21:11 - 6; http://dx.doi.org/10.1021/bp040016j; PMID: 15903235
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs 2012; 4:1 - 7; http://dx.doi.org/10.4161/mabs.20996; PMID: 22327425
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008; 9:482 - 501; http://dx.doi.org/10.2174/138920108786786411; PMID: 19075687
   PubMed Web of Science ®Google Scholar
• Beck A, Cochet O, Wurch T. GlycoFi’s technology to control the glycosylation of recombinant therapeutic proteins. Expert Opin Drug Discov 2010; 5:95 - 111; http://dx.doi.org/10.1517/17460440903413504; PMID: 22823974
   PubMed Web of Science ®Google Scholar
• Damen CWN, Chen W, Chakraborty AB, van Oosterhout M, Mazzeo JR, Gebler JC, et al. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J Am Soc Mass Spectrom 2009; 20:2021 - 33; http://dx.doi.org/10.1016/j.jasms.2009.07.017; PMID: 19744865
   PubMed Web of Science ®Google Scholar
• Wilm MS, Mann M. Electrospray and Taylor-Cone theory, Dole’s beam of macromolecules at last?. Int J Mass Spectrom Ion Process 1994; 136:167 - 80; http://dx.doi.org/10.1016/0168-1176(94)04024-9
   Web of Science ®Google Scholar